9c(i472) is an inhibitor of 15-lipoxygenase-1 (15-LO-1; IC50 = 0.19 μM).1 It decreases LPS- and IFN-γ-induced NF- B activity in RAW-Blue cells when used at concentrations of 0.2, 1, and 5 μM. 9c(i472) reduces LPS- and IFN-γ-induced increases in Nos2 expression and lipid peroxidation in RAW 264.7 cells when used at a concentration of 5 μM.

COX-2/15-LOX-IN-1 (Compound 14) is a COX-2 and 15-lipoxygenase (15-LOX) inhibitor that acts on COX-1 (IC50: 10.65 μM), COX-2 (IC50: 0.075 μM) and 15-LOX (IC50: 2.98 μM). 25 has an anti-inflammatory effect.

CAY10698 is a 12-lipoxygenase inhibitor (12-LO; IC50 of 5.1 µM).

Compound 105 (h15-LOX-2 inhibitor 1) is a potent inhibitor of human epithelial 15-lipoxygenase-2 (h15-LOX-2), exhibiting an IC50 of 0.34 μM [1].

COX-2/15-LOX-IN-2 is a potent inhibitor of both COX-2 and 15-LOX, demonstrating IC50 values of 0.065 μM for COX-2 and 1.86 μM for 15-LOX. Additionally, it exhibits significant antioxidant activity [1].

COX-2-IN-26 is a potent, orally active, selective COX-2 inhibitor that acts on COX-1 (IC50: 10.61 μM), COX-2 (IC50: 0.067 μM), and 15-LOX (IC50: 1.96 μM).COX-2-IN-26 is anti-inflammatory and has a gastrointestinal safety profile.

WES-1 (Compound 8g), a carbonic anhydrase IX inhibitor (Ki: 55.9 μM), exhibits broad-spectrum antiproliferative activity against various cancer cell lines, including leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI-H460), colon cancer (HCT 116 and HCT-15), and melanoma (LOX IMVI) [1].

COX-2/15-LOX-IN-4 (compound 5i) is a dual inhibitor with IC50 values of 0.075 μM for COX-2 and 1.97 μM for 15-LOX. It inhibits LPS-induced production of pro-inflammatory cytokines (IL-6, ROS) and exhibits targeted anti-inflammatory effects [1].

COX-2-IN-28 is a potent and selective COX-2 inhibitor capable of acting on COX-2 (IC50: 0.054 μM), 15-LOX (IC50: 2.14 μM) and COX-1 (IC50: 13.21 μM).

15-Lipoxygenase Inhibitor 1 is a selective inhibitor of 15-lipoxygenase, with an IC50 of 18 μM. 4-MMPB (15-Lipoxygenase Inhibitor 1) has IC50s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer.

COX-2/15-LOX-IN-3 (compound 5k) serves as a dual inhibitor for COX-2 and 15-LOX, demonstrating inhibitory concentrations (IC50) of 0.075 μM and 1.97 μM, respectively. This compound effectively suppresses LPS-induced cellular production of pro-inflammatory cytokines (IL-6, ROS, and NO), exhibiting targeted anti-inflammatory effects [1].

ML351 is a potent and selective inhibitor of human 15-lipoxygenase-1 (15 LOX)(IC50: 200 nM).

ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor with IC50 value of 12 μM. ThioLox shows anti-inflammatory and neuroprotective properties. It has anti-inflammatory and neuroprotective effects, and has a strong protective effect against glutamate toxicity.